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A pan-cancer analysis of driver gene
mutations, DNA methylation and gene
expressions reveals that chromatin
remodeling is a major mechanism inducing
global changes in cancer epigenomes
Ahrim Youn1,2, Kyung In Kim2, Raul Rabadan3,4, Benjamin Tycko5, Yufeng Shen3,4,6 and Shuang Wang1*
Abstract
Background: Recent large-scale cancer sequencing studies have discovered many novel cancer driver genes
(CDGs) in human cancers. Some studies also suggest that CDG mutations contribute to cancer-associated
epigenomic and transcriptomic alterations across many cancer types. Here we aim to improve our understanding
of the connections between CDG mutations and altered cancer cell epigenomes and transcriptomes on pan-cancer
level and how these connections contribute to the known association between epigenome and transcriptome.
Method: Using multi-omics data including somatic mutation, DNA methylation, and gene expression data of 20
cancer types from The Cancer Genome Atlas (TCGA) project, we conducted a pan-cancer analysis to identify CDGs,
when mutated, have strong associations with genome-wide methylation or expression changes across cancer types,
which we refer as methylation driver genes (MDGs) or expression driver genes (EDGs), respectively.
Results: We identified 32 MDGs, among which, eight are known chromatin modification or remodeling genes.
Many of the remaining 24 MDGs are connected to chromatin regulators through either regulating their
transcription or physically interacting with them as potential co-factors. We identified 29 EDGs, 26 of which are also
MDGs. Further investigation on target genes’ promoters methylation and expression alteration patterns of these 26
overlapping driver genes shows that hyper-methylation of target genes’ promoters are significantly associated with
down-regulation of the same target genes and hypo-methylation of target genes’ promoters are significantly
associated with up-regulation of the same target genes.
Conclusion: This finding suggests a pivotal role for genetically driven changes in chromatin remodeling in shaping
DNA methylation and gene expression patterns during tumor development.
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gene, expression driver gene, chromatic remodeling
* Correspondence: sw2206@columbia.edu
1Department of Biostatistics, Mailman School of Public Health, Columbia
University, New York, New York, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Youn et al. BMC Medical Genomics           (2018) 11:98 
https://doi.org/10.1186/s12920-018-0425-z
Background
Cancer arises through accumulation of somatically acquired
genetic and epigenetic aberrations that lead to malignant
transformation [1, 2]. Comprehensive characterization of
somatic mutations in cancer genomes using next-genera-
tion sequencing technology has led to discoveries of cancer
driver genes (CDGs) in human cancers [2]. The interplay
between genetic and epigenetic alterations was only re-
cently revealed through genome-wide scale genomic and
epigenomic analyses. Specifically, genome-wide change of
DNA methylation was observed in patients with mutations
in epigenetic regulators [2–4], affecting both the global
levels of 5-methyl-cytosine (5mC) and the precise DNA
methylation patterns in diverse regulatory sequences across
the genome [2, 3]. A recent study investigated associations
between driver gene mutations and DNA methylation alter-
ations across many cancer types [5], and identified associa-
tions between mutated driver genes and site-specific
methylation changes as well as some genome-wide trends
in specific cancer types. They further used these
mutation-methylation associations to better define cancer
subtypes. However, it remains largely unknown how the
CDG mutations contribute to changes in cancer cell epi-
genomes on a pan-cancer level [6]. A better understanding
of the connections between CDGs and altered cancer cell
epigenomes is an important goal, particularly since muta-
tions in epigenetic regulators could be novel targets for
anti-cancer therapies [6].
Studies have integrated multi-scale omics data, includ-
ing somatic mutation data, epigenomes, and transcrip-
tomes across various cancer types to improve the
mechanistic understanding of the interplay between can-
cer genome and cancer epigenome and transcriptome.
An integrative analysis of DNA methylation data and
gene expression data of various cancer types identified
pan-cancer hypo- and hyper-methylated genes that are
predictive of transcription as well as methylation-driven
subgroups with clinical implications [7]. Another inte-
grative analysis on a set of known epigenetic regulators
with DNA methylation data and gene expression data
from various cancer types identified key epigenetic regu-
lators whose deregulation patterns are associated with
genome-wide DNA methylation changes, which tran-
scend cancer types [8].
Here we aim to improve our understanding of the
connections between CDGs and altered cancer cell epi-
genomes and altered cancer cell transcriptome on
pan-cancer level, and how these connections contribute
to the known association between cancer epigenome
and transcriptome. We used somatic mutation, DNA
methylation, and gene expression data of 20 cancer types
from The Cancer Genome Atlas (TCGA) project to
identify CDGs that, when mutated, have strong associa-
tions with genome-wide methylation or expression
changes across cancer types, which we refer as methyla-
tion driver genes (MDGs) or expression driver genes
(EDGs). We identified 32 MDGs and found that most of
them are either chromatin regulators (genes involved in
chromatin remodeling) or ones that regulate the expres-
sion of or physically interact with chromatin regulators.
We also identified 29 EDGs and found that 26 of
them overlap with the 32 MDGs. We further investi-
gated target genes’ methylation and expression alter-
ation patterns that are associated with mutation
status of these 26 overlapping driver genes and found
that hyper-methylation of target genes’ promoters are
significantly associated with down-regulation of the
same target genes and hypo-methylation of target
genes’ promoters are significantly associated with
up-regulation of the same target genes. This finding
shows that dysregulation of chromatin regulators is
potentially an important mechanism that induces glo-
bal change of DNA methylation and gene expression
in tumor development.
Methods
We downloaded somatic mutation data, DNA methylation
450K array data, and gene-level RNA-seq data of 20
tumor types with at least 100 samples available in all three
data types from TCGA. For DNA methylation 450K array
data, we conducted standard quality control steps remov-
ing CpG sites that overlap with known single nuclear
polymorphisms (SNPs), sites on the sex chromosomes and
sites with missing values for more than 5% of the tumor
samples within a tumor type. After these steps, 370,877
CpG sites remained. We then corrected for the type I/II
probe bias using the BMIQ algorithm [9]
Selection of candidate CDGs
We obtained level 2 somatic mutation data of the
above-mentioned 20 tumor types from Broad Institute
TCGA Genome Data Analysis Center Firehose [10] and
selected candidate CDGs using the MutSIG [11] algo-
rithm that tests how frequently a gene is mutated in a
tumor type comparing to the background mutation rate.
We used the false discovery rate (FDR) < 0.1 to select
candidate CDGs. We then assessed the functional im-
pact of mutations at gene levels using the MutationAs-
sessor [12] algorithm to further remove mutations
classified as neutral. Additional steps were done for
COAD and STAD when an abnormally large number of
candidate CDGs remained (1,433 and 553, respectively)
after these steps to avoid potential high false positive
discovery rate of CDGs. Specifically, we only kept the
genes that were identified in any of the other 18 tumor
types as well as identified in the Cancer Gene Census
[13] and the numbers of candidate CDGs in COAD and
STAD then dropped to 193 and 67. The number of
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candidate CDGs selected in all 20 tumor types is pro-
vided in Additional file 1: Table S1.
To conduct pan-cancer analysis associating mutation and
methylation/expression, within a tumor type, we selected
CDGs that have mutations in at least 5 samples with
matched methylation data or expression data in order to
have not-too-sparse numbers in the mutated group. For
matched mutation and methylation data, 445 CDGs were
selected across the 20 tumor types. Here we analyzed som-
atic mutations at the gene level and a gene is considered
mutated in a tumor sample as long as there is any mutation
in this gene. Within these driver genes, the number of
tumor types in which a driver gene was mutated in at least
five samples varies from 1 to 15 (Additional file 2: Table S2)
where most of the CDGs were mutated in only one or two
tumor types. TP53 was mutated in 15 tumor types and
PTEN was mutated in 14 tumor types. For matched muta-
tion data and expression data, 422 CDGs were similarly se-
lected. Of them, 403 CDGs overlap with the CDGs selected
for matched mutation data and methylation data. For the
422 CDGs, the number of tumor types in which a CDG is
mutated in at least five samples varies from 1 to 14 (Add-
itional file 2: Table S2), where TP53 and PTEN were mu-
tated in 14 tumor types.
Pan-cancer analysis to identify MDGs
We described the details in the pan-cancer analysis associ-
ating driver genes and genome-wide methylation alter-
ations across cancer types. Similar procedures with
necessary modifications to associate driver genes and gene
expression changes were described in the Additional file 3:
Text S1.
Associate CDGs and DNA methylation in one cancer type
For CDG i, let Ai denote the set of tumor types in which
CDG i is mutated in at least 5 tumor samples with
methylation data available. We then determine the
hyper- or hypo-methylation status per CpG site by the
mutation status of CDG i using the nonparametric
Wilcoxon test. Since methylation levels range from 0 to
1 and are often bimodally distributed across tumor sam-
ples and the numbers of samples in the mutated and
non-mutated groups are extremely unbalanced. With
the Wilcoxon test, we define a set of genome-wide
hyper-methylated sites Si,k+ whose methylation levels are
significantly increased at significance level 0.01 in the
mutated group comparing to the non-mutated group of
CDG i in cancer type k. We similarly define a set of
hypo-methylated sites Si,k−. Since the goal is not to iden-
tify specific CpG sites that are affected by the mutation
status but to see how the mutation status is associated
with genome-wide methylation changes, no multiple
comparisons adjustment is applied to the site-level dif-
ferential methylation association test.
To determine if mutation status of CDG i is signifi-
cantly associated with genome-wide methylation changes
in cancer type k, we calculate the p-value pi,k, which is
the probability of observing the number of differentially
(hyper- or hypo-) methylated sites nmi;k ¼ j Sþi;k∪S−i;k j or
more that are associated with the mutation status of
CDG i in cancer type k under the null hypothesis that
the mutation status of CDG i is not associated with
genome-wide methylation changes. To do so, we gener-
ate a “methylation null pool”, which has the number of
differentially methylated sites under the null hypothesis.
We first selected genes that were mutated in at least 5
samples with methylation data available within a tumor
type. We then further selected only top 500 highly mu-
tated genes within each tumor type for computational
efficiency and also excluded the 445 CDGs selected
above. We ended up with 7,019 mutation genes (those
are considered as passenger mutation genes) across 20
tumor types in the “methylation null pool” (see Add-
itional file 4: Table S3 for the number of mutation genes
from each tumor type). The 7,019 mutation genes have
similar mutation rate (average number of mutations in a
cancer type) with that of the 445 CDGs. The average
mutation rate of these 7,019 mutation genes is 0.082
with standard deviation (SD) 0.10 while the average mu-
tation rate of the 445 CDGs is 0.085 with SD = 0.13
(p-value=0.54 from a t-test).
Within each cancer type, we calculated nmjnull , the num-
ber of differentially methylated sites that are associated
with the mutation status of the methylation null gene
jnull= 1,…,7019, which form the “methylation null pool”.
The p-value pi,k, is then calculated as the proportion of
numbers nmjnull in the “methylation null pool” that is greater
than or equal to the observed number of differentially
methylated sites nmi;k , that is, pi,k=
1
7019
P7019
jnull¼1 Iðnmi;k ≤nmjnull Þ
, where I(.) is the indicator function.
To investigate the potential selection bias in the
“methylation null pool”, we also generated the null dis-
tribution of number of genome-wide differentially meth-
ylated sites by randomly splitting tumor samples of a
tumor type into mutation and non-mutation groups,
varying the percentage of mutation from 5 to 40% based
on the mutation rate of the TCGA 20 tumor types and
calculated numbers of differentially methylated sites be-
tween the two groups. We repeated this 10 times for
each percentage from 5 to 40%, increasing by 1%. There-
fore, we ended up with 360*20 values for the number of
differentially methylated sites across 20 tumor types. We
found that these numbers are on average much smaller
than those from the “methylation null pool” generated
using passenger mutations, making the p-values of
CDGs more significant. This indicates that there is some
association between passenger mutations and global
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methylation changes that random sampling cannot
capture. Therefore, the methylation null pool generated
by using the passenger mutations rather than randomly
splitting may represent a better null distribution. The
MDGs identified this way are those associated with
methylation changes beyond what is expected for pas-
senger mutations.
We classify the effect of CDG i on genome-wide
methylation in tumor type k as:
CDG i in tumor type k
¼
genome‐wide hyper‐methylated if pi;k < 0:05 jSþi;k j > jS−i;k j
 
genoem‐wide hypo‐methylated if pi;k < 0:05 jSþi;k j≤ jS−i;k j
 
:
8<
:
Associate CDGs and DNA methylation across multiple
cancer types
To calculate the p-value, pi, testing if CDG i is signifi-
cantly associated with genome-wide methylation changes
across multiple cancer types, we compare
P
k∈Ain
m
i;k , the
observed total number of differentially methylated sites
associated with CDG i summed over Ai cancer types, to
B resampled values generated from the “methylation null
pool” where we set B=one million. More specifically, for
CDG i that was mutated in |Ai| number of tumor types,
the null distribution is generated using the B sets of sum
of |Ai| random samples from the “methylation null
pool”. We then calculate pi as follows:
pi ¼
XB
b¼1I
X
k∈Ai
nmi;k ≤
XjAij
j¼1n
m
rb; j
 
=B;
where rb, j is a random number between 1 and 7,019
from the bth resampling. We use Benjamini-Hochberg
procedure to adjust for multiple comparisons on pi,
which is done within groups of CDGs that were mutated
in the same number of tumor types. The MDGs are then
identified as those CDGs with adjusted pi < 0.05.
Results
TCGA 20 Cancer Types
We assembled somatic mutation data, HM450 DNA
methylation data and gene-level RNA-Seq data (upper--
quantile-normalized count data) of 20 tumor types with
at least 100 samples available in all three data types from
TCGA. This includes breast invasive carcinoma (BRCA),
bladder urothelial carcinoma (BLCA), cervical squamous
cell carcinoma (CESC), colon adenocarcinoma (COAD),
glioblastoma (GBM), head and neck squamous cell car-
cinoma (HNSC), kidney renal clear cell carcinoma
(KIRC), kidney renal papillary cell carcinoma (KIRP),
acute myeloid leukemia (LAML), lower grade glioma
(LGG), liver hepatocellular carcinoma (LIHC), lung
adenocarcinoma (LUAD), lung squamous cell carcinoma
(LUSC), pancreatic adenocarcinoma (PAAD), pheochro-
mocytoma and paraganglioma (PCPG), prostate adeno-
carcinoma (PRAD), sarcoma (SARC), stomach
adenocarcinoma (STAD), thyroid carcinoma (THCA),
testicular germ cell tumor (TGCT), and uterine corpus
endometrial carcinoma (UCEC)). For detailed steps on
processing DNA methylation data and selecting candi-
date CDGs, see Methods. We refer candidate CDGs as
CDGs from now on for notation simplicity.
The Pan-Cancer Analysis
We conducted a pan-cancer analysis to identify methyla-
tion driver genes (MDGs)/expression driver genes
(EDGs) that, when mutated, have strong associations
with genome-wide methylation/expression changes
across multiple cancer types through integrating somatic
mutation and DNA methylation/gene expression data of
20 TCGA tumor types (Fig. 1a, b).
We then showed that some of the identified MDGs
are chromatin regulators that directly affect the
genome-wide methylation patterns and some are con-
nected to chromatin regulators through either regulating
their transcription or physically interacting with them as
potential co-factors (Fig. 1c).
We first tested whether mutations in a CDG are sig-
nificantly associated with changes in genome-wide
methylation patterns in one cancer type. For this, we
performed CpG-site-level association analysis within a
cancer type, where a nonparametric Wilcoxon test was
used since the numbers of samples in the mutated and
non-mutated groups are extremely unbalanced and
methylation measures were usually enriched at 0 and 1
[14]. We then used the number of genome-wide differ-
entially methylated sites as the test statistic to measure
degree of genome-wide methylation changes associated
with the mutation status of a CDG for one cancer type.
Note that we used significance level 0.01 to determine
site-level association without multiple comparisons
adjustment since the goal is to measure genome-wide
degree of differential methylation due to mutation status
but not to claim any associated CpG sites. To assess the
significance of the genome-wide methylation changes by
a CDG in one cancer type, we first generated an empir-
ical null distribution with numbers of genome-wide dif-
ferentially methylated sites by mutations of non-CDGs
and then calculated the p-value pi,k for CDG i in cancer
type k by comparing the number of genome-wide differ-
entially methylated sites by the mutation of CDG i in
cancer type k with the empirical null distribution. We
then classify the effect of CDG i in tumor type k as
hyper-methylated if pi,k<0.05 and the number of
genome-wide hyper-methylated sites is greater than that
of hypo-methylated sites or hypo-methylated if pi,k<0.05
and the number of genome-wide hypo-methylated sites
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is greater than that of hyper-methylated sites. Finally, to
determine the significance of genome-wide methylation
changes across multiple cancer types by a CDG, we
compare the observed total number of differentially
methylated sites associated with a CDG summed over all
cancer types with its null distribution to calculate the
p-value pi. We use Benjamini-Hochberg procedure to
adjust for multiple comparisons for pi, where the adjust-
ment is done within the group of CDGs that were mu-
tated in the same number of cancer types. The MDGs
are then identified as those CDGs with adjusted p-values
< 0.05. Similar steps are applied to mutation and expres-
sion data to identify EDGs. Detailed steps of how to
identify MDGs/EDGs are provided in the Methods.
Thirty-two MDGs were identified that, when mutated,
have strong association with genome-wide methylation
changes across 20 cancers
The pan-cancer analysis of the 20 TCGA cancer types
identified 32 MDGs (Table 1). For the complete list of
CDGs whose mutation states were significantly associ-
ated with genome-wide methylation changes within each
cancer type (gene i with pi,k<0.05 in the cancer type k),
see Additional file 5: Table S4. The genes in Table 1 and
Additional file 5: Table S4 highly overlap with the genes
identified as the CDGs whose mutation states are associ-
ated with genome-wide methylation changes by Chen
et al. [5]. They used Principal Component Analysis
(PCA) to identify driver genes whose mutations are
Fig. 1 Rationale underlying the pan-cancer analysis to identify (a) MDGs that are associated with genome-wide methylation changes across cancer
types and (b) EDGs that are associated with genome-wide expression changes across cancer types, with further analysis that reveals (c) MDGs mostly
consist of chromatin regulators that directly affect the genome-wide methylation patterns or genes that regulate expression of or physically interact
with chromatin regulator.
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associated with the top five PCs within each cancer. Al-
though the two methods used different approaches, the
identified genes are very similar, providing further valid-
ation of the results.
The 32 MDGs were mutated with different frequencies
in each cancer types (Additional file 6: Figure S1) and the
mutation status of the 32 MDGs is associated with differ-
ent genome-wide number of hyper- and hypo-methylated
sites (Fig. 2a). Cancer types COAD and STAD have the
highest mutation rate with many of the identified MDGs
being mutated. KIRP, PCPG, TGCT and THCA have the
smallest number of mutated MDGs. In CESC, LUSC,
Table 1 The identified 32 MDGs
MDGs |Ai| |Ti| Pi Di T
-
i T
+
i
TP53 15 8 < e-06 botha BLCA BRCA HNSC LIHC
LUAD STAD UCEC
LGGa
PTEN 14 3 0.00147 both LGG STAD UCEC
RB1 11 2 0.00861 both LGG BLCA
PIK3CA 11 1 0.0277 hyper STAD
ARID1A 10 1 0.0401 hyper STAD
KRAS 8 1 1.2e-05 hypo TGCT
KMT2D 8 2 0.00575 both BLCA STAD
NF1 6 2 0.000227 hypo LGG PCPG
CTNNB1 6 2 0.00185 hypo LIHC UCEC
SETD2 5 2 0.00351 hyper KIRC KIRP
KMT2C b 5 1 0.00681 hyper STAD
EGFR 4 1 9.5e-05 hypo LGG
HRAS 4 2 0.000266 both PCPG HNSC
BRAF 4 2 0.00474 both THCA COAD
IDH1 3 2 < e-06 hyper GBM LGG
CIC 3 1 1.3e-05 hyper LGG
NRAS 3 2 1.4e-05 both TGCT THCA
RNF43 3 2 5.1e-05 both STAD COAD
ATRX 3 1 0.000487 hypera LGGa
ZBTB20 3 2 0.00151 hyper COAD STAD
NOTCH1 3 1 0.00189 hyper LGG
CDH1 3 2 0.00213 hyper BRCA STAD
KEAP1 3 1 0.00578 hypo LUAD
SMARCA4 3 1 0.00687 hypo LUAD
FOXA1b 3 1 0.00953 hypo PRAD
EPHA2b 3 1 0.0104 hyper STAD
KIT 2 1 < e-06 hypo TGCT
KMT2B 2 2 0.000511 both STAD COAD
FGFR3b 2 1 0.000697 hypo BLCA
STK11b 2 1 0.00193 hypo LUAD
NSD1 1 1 < e-06 hypo HNSC
BAP1b 1 1 0.000142 hyper LIHC
|Ai|: number of tumor types in which CDG i is mutated in ≥ 5 samples with available methylation data;
|Ti|: number of tumor types whose genome-wide methylation levels are significantly associated with the mutation status of CDG i;
pi: p-value testing if CDG i is significantly associated with genome-wide methylation changes across tumor types;
Di: direction of methylation changes associated with mutation status of CDG i;
T+i: tumor types that are hyper-methylated by CDG i;
T-i: tumor types that are hypo-methylated by CDG i;
a: Further stratified analysis by IDH1 mutation status in LGG tumor samples suggests an opposite direction from hyper- to hypo-methylation;
b: genes that are not overlapping driver genes
__ : genes that are identified as associated with genome-wide patterns of aberrant methylation by Chen et al. [5]
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PAAD, and SARC tumor types, genome-wide methylation
patterns were not significantly affected by mutations of
any of the identified 32 MDGs, potentially due to small
sample sizes or fewer number of CDGs. TP53 mutations
are associated with significant genome-wide methylation
changes in 8 out of the 15 tumor types in which it was
mutated in more than 5 samples (Table 1). Among these 8
tumor types, more CpG sites were hypo-methylated in all
but LGG. Instead, in LGG, TP53 mutations are associated
with more hyper-methylated CpG sites. However, almost all
LGG tumors with TP53 mutations also have IDH1 muta-
tions (Additional file 6: Figure S1), which are known to lead
to hyper-methylation in LGG [15–17]. IDH1 is also identi-
fied as one of the 32 MDGs, where in GBM and LGG, it is
associated with more CpGs to be hyper-methylated. Given
the prominent role of IDH1 in LGG, we stratified LGG
tumor samples by the IDH1 mutation status and further
examined the effect of the other 31 MDGs within the IDH1
mutation stratum and the IDH1 wild-type stratum and
found that TP53 mutations are now significantly associated
with more hypo-methylation genome-wide in each stratum
(Additional file 3: Text S1). Similar stratified analyses were
conducted in all other tumor types whose genome-wide
methylation patterns were significantly associated with
mutations of the identified MDGs. Similar patterns as in
the non-stratified analysis were observed (Additional file 7:
Table S5).
Many MDGs are known chromatin regulators or the ones
that regulate the expression of or physically interact with
chromatin regulators
Among the identified 32 MDGs, 8 are known chromatin
regulators that are either histone modification enzymes
(KMT2D, KMT2C, KMT2B, NSD1, and SETD2), or part
Fig. 2 a Number of genome-wide hyper- (1) and hypo-methylated (2) sites that are associated with the mutation status of the 32 identified MDGs
(columns) for each of the 20 TCGA tumor types (rows). (b) Number of genome-wide up-regulated- (1) and down-regulated- (2) genes that are associated
with the mutation status of the 29 identified EDGs (columns) for each of the 20 TCGA tumor types (rows). The color code represents the number of
differentially methylated sites/differentially expressed genes. Only driver genes that were mutated in ≥ 5 samples for the given tumor type were colored
Youn et al. BMC Medical Genomics           (2018) 11:98 Page 7 of 16
of ATP-dependent chromatin remodeling complexes
(ARID1A, ATRX, and SMARCA4, all from the SWI/SNF
family [18]).
We hypothesize that among the remaining 24 MDGs,
some are “epigenetic modulators” in that these genes
change genome-wide methylation patterns by regulating
the expression of chromatin regulators/DNA methyl-
transferases, or through physically interacting with these
epigenomic regulators as cofactors. To test this hypoth-
esis, we examined whether mutations of these 24 MDGs
are associated with the expression changes of known
epigenomic regulator genes across the 20 tumor types,
where we used the exon level RNA-Seq data of the 20
tumor tissue types from TCGA. We also investigated if
epigenomic regulator genes are over-represented among
genes that physically interact with these 24 MDGs.
We created two lists of known chromatin regulator
genes. List A has 720 DNA/RNA, histone and chromatin-
modifying enzymes and their co-factors from the EpiFac-
tors database [19]. List B has 18 epigenetic regulators that
were identified as the master regulators of global DNA
methylation by Yang et al. [8], including EYA4, SETBP1,
PRDM2, PRDM5, CBX7, DUSP1, KAT2B, RAD54L,
WHSC1, EZH2, UHRF1, PCNA,TTF2, KDM1A, SUV39H2,
HDAC1, TDG and TET3, plus the DNA methyltransferase
DNMT1, 3A, 3B that were not identified as master regula-
tors by Yang et al. [8].
Among the remaining 24 MDGs that are potentially
new “epigenetic modulators”, 12 are associated with
genome-wide methylation changes in more than one
cancer type (Table 1), including TP53, PTEN, RB1, NF1,
CTNNB1, HRAS, BRAF, IDH1, NRAS, RNF43,ZBTB20,
and CDH1. To focus on pan-cancer effects, we worked
on only these 12 driver genes that are associated with
genome-wide methylation changes in more than one
cancer types. For each of these 12 genes, we first identi-
fied genome-wide target genes whose expression levels
were dysregulated by the mutation status commonly
across tumor types. We compared the expression levels
of all genes between mutated and non-mutated groups
of a MDG using a two-sample t-test and identified target
genes that show significantly differential expressions
(p-value <0.05) in all tumor types whose methylation
patterns are associated with the mutation status. Simi-
larly, since the goal here is not to identify specific target
genes that are affected by the MDGs but to quantify
degree of dysregulation by MDGs through number of
target genes that are commonly dysregulated across can-
cer types, we used a loose p-value cutoff without consid-
ering multiple comparisons. We then examined if
known chromatin regulators in lists A and B were over
represented among the genome-wide dysregulated target
genes by a MDG. The expression data were only avail-
able for 717 out of the 720 genes in list A, but were
available for all 21 genes in list B. We used a hypergeo-
metric distribution to calculate p-values for the enrich-
ment of known chromatin regulators and described the
procedure to examine this mechanistic hypothesis in
more details in Fig. 3.
We found that among the genome-wide dysregulated
target genes by each of the 12 MDGs, known chromatin
regulators were clearly enriched (Table 2). In addition, 7
out of the 12 MDGs are associated with differential
expression of the DNMT genes. Additionally, the results
in Table 2 confirm some previously known interactions
between MDGs and chromatin regulators. For example,
TP53 mutations are associated with upregulated KDM1A
expression levels across all tumor types whose
genome-wide methylation patterns are also significantly
associated with TP53 mutations. KDM1A is known to
physically interact with TP53 [20] and it demethylates
histone lysine residues 9 of histone 3, which in turn
leads to extensive hypo-methylation in that region
[21]. This analysis suggests that KDM1A may play a
role in the association between TP53 mutations and
genome-wide hypo-methylation changes across tumor
types. Other notable associations that were confirmed
by results in Table 2 include interactions between
RB1 and DNMT1, and between RAS genes (HRAS,
NRAS) and HDAC1 [22].
We next investigated if the epigenomic regulator genes
in lists A and B are over represented among genes that
physically interact with these 12 MDGs. To do so, we
first obtained a list of genes that physically interact with
each of them from the HumanMine database [23]. We
then tested if the epigenomic regulator genes in lists A
and B are over-represented among them. Since the num-
ber of physically interacting genes was too small for
some MDGs, the enrichment analysis was only con-
ducted for the genes in list A that had enough overlap
with the interacting genes. We found that known epige-
nomic regulator genes in list A were highly enriched in
the lists of interacting genes of the 12 MDGs (Table 3).
These results support our hypothesis that these 12
MDGs that are not known chromatin regulators but are
associated with changes in epigenomes either through
regulating expression of epigenomic regulators or
through physically interacting with them.
We also investigated whether differential expression of
target genes in list B of 21 epigenetic regulators are dir-
ectly or indirectly associated with differential methyla-
tion of the same genes. We found only a small fraction
of genes in list B whose expression and methylation
levels are both associated with the mutation status of the
MDGs (Table 2), which suggests that the differential
expression of these target genes may be directly associ-
ated with mutations of these MDGs instead of being
indirectly associated through changes in their
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methylation patterns. We further investigated mutation
status of genes in list B to examine if the mutations
affect their expression or methylation levels directly and
found that the majority of genes in list B were rarely
mutated across tumor types (Additional file 8: Table S6).
Although CIC was not included in the above analyses
since it was mutated only in LGG, due to its important
role in LGG tumors, we examined how CIC regulates
expressions of target genes and found that chromatin
remodeling genes in list A were significantly enriched
Fig. 3 Steps to test if chromatin regulators are enriched among the dysregulated target genes associated with the mutation status of the
identified MDGs
Table 2 MDGs dysregulate expression levels of chromatin regulators
MDGs |Ti| N1 (# of
dysregulated
genes)
N2 (# of
dysregulated
genes in list
A)
Enrichment
PvalueA
N3 (# of
dysregulated
genes in list
B)
Enrichment
PvalueB
Genes in list B that are dysregulateda Genes in list B
that are
differentially
methylatedb
TP53 8 233 19 0.00056 5 3.2e-06 CBX7 RAD54L TTF2 KDM1A SUV39H2
PTEN 3 1,534 81 0.00012 9 9.1e-06 DNMT1 DNMT3A SETBP1 PRDM5 CBX7 RAD54L
EZH2 PCNA HDAC1
DNMT3A
PRDM5 HDAC1
RB1 2 1,447 83 5.2e-06 4 0.056 DNMT1 EYA4 EZH2 PCNA PCNA
NF1 2 766 36 0.044 0 1
CTNNB1 2 5,515 207 0.12 12 0.0033 DNMT1 SETBP1 PRDM2 PRDM5 CBX7 KAT2B
RAD54L WHSC1 EZH2 UHRF1 TDG TET3
PRDM2 CBX7
HRAS 2 1,137 63 2.0e-04 3 0.11 PRDM2 RAD54L HDAC1 PRDM2
BRAF 2 3,128 133 0.008 8 0.0091 DNMT1 DNMT3A DNMT3B KAT2B WHSC1 EZH2
UHRF1 KDM1A
DNMT3A
UHRF1
IDH1 2 3,560 208 2.8e-15 2 0.9 SUV39H2 TET3
NRAS 2 1,609 87 2.8e-05 1 0.82 HDAC1
RNF43 2 3,212 157 4.4e-06 8 0.011 DNMT3A DNMT3B PRDM2 RAD54L WHSC1
UHRF1 HDAC1 TET3
DNMT3A
DNMT3B
PRDM2 WHSC1
ZBTB20 2 1,563 78 0.00088 6 0.0039 DNMT3A RAD54L WHSC1 UHRF1 TTF2 HDAC1 DNMT3A
WHSC1 UHRF11
CDH1 2 2,792 136 2.7e-05 14 3.3e-08 DNMT3B SETBP1 PRDM2 CBX7 DUSP1 RAD54L
WHSC1 EZH2 PCNA KDM1A SUV39H2 HDAC1
TDG TET3
PRDM2 CBX7
WHSC1 KDM1A
|Ti|: number of tumor types whose genome-wide methylation levels are significantly associated with the mutation status of CDG i;
N1: number of genes whose expression levels are dysregulated by MDG i in all |Ti| tumor types;
N2: number of genes in list A that are dysregulated in all |Ti| tumor types;
N3: number of genes in list B that are dysregulated in all |Ti| tumor types;
Enrichment PvalueA, and PvalueB are calculated using hypergeometric distributions testing if genes in lists A and B are enriched among genome-wide
differentially expressed target genes;
aGenes in list B that are dysregulated in all |Ti| tumor types;
bGenes in list B that are differentially methylated in all |Ti| tumor types.
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among dysregulated target genes, in both full LGG
tumor samples and in stratified samples by IDH1 muta-
tion status (Additional file 9: Table S7).
Twenty-nine EDGs were identified, out of which, 26
overlaps with the identified 32 MDGs
We conducted similar pan-cancer analysis to associate
driver genes and gene expression across the 20 TCGA
cancer types. We identified 29 CDGs as the expression
driver genes (EDGs) that, when mutated, are signifi-
cantly associated with genome-wide expression changes
across multiple cancer types (Table 4). The mutation
status of these 29 EDGs is associated with different
genome-wide number of up- and down-regulated genes
(Fig. 2b). For the complete list of CDGs whose mutation
states were significantly associated with genome-wide
expression changes within each cancer type, see Add-
itional file 10: Table S8.
Of the 29 EDGs, 26 overlap with the 32 MDGs. To
understand this high rate of overlap, within each cancer
type, we examined the overlap between CDGs that are
significantly associated with genome-wide methylation
changes and CDGs that are significantly associated with
genome-wide expression changes, and found they over-
lap highly. Moreover, there is a high correlation between
the number of differentially methylated sites and the
number of differentially expressed genes by each CDG
(Additional file 11: Table S9), which implies a close con-
nection between genome-wide methylation changes and
genome-wide expression changes.
We further investigated patterns of target genes’
methylation in promoter regions and target genes’ ex-
pression changes of the 26 overlapping driver genes. A
target gene is hyper-methylated if the number of
hyper-methylated sites is larger than that of
hypo-methylated in the promoter region of the gene
(1,500 base pairs upstream of the transcription start site)
and hypo-methylated otherwise. If there are the same
numbers of hyper-/hypo-methylated sites or no hyper/
hypo-methylated sites in the promoter region, the gene
is considered not differentially methylated. The signature
patterns of target genes’ methylation and expression
changes by the overlapping driver genes could be
hyper-methylated and up-regulated, the “++” pattern;
hyper-methylated and down-regulated, the “+-” pattern;
hypo-methylated and up-regulated, the “-+” pattern; and
hypo-methylated and down- regulated, the “--” pattern.
We used a hypergeometric distribution to calculate
p-values for the enrichment of each pattern in a cancer
type and combined per tumor type p-values using the
Fisher’s method (Additional file 12: Figure S2, Table 5).
It is clear that across the 26 overlapping driver genes,
target genes’ hyper-methylation are significantly associ-
ated with their down-regulation (“+-” pattern) and target
genes’ hypo-methylation are significantly associated with
their up-regulation (“-+” pattern). A specific example of
a target gene that is hypo-methylated and up-regulated by
the mutation of TP53 is HSF1 gene. It is hypo-methylated
and up-regulated by TP53 mutations across 9 tumor
types. Dysregulation of chromatin regulators induces glo-
bal change of chromatin architecture, which is highly in-
terconnected with DNA methylation. DNA methylation
and histone modification interact with each other to de-
termine the chromatin state as an euchromatic (on) or
heterochromatic (off) state, where euchromatic state is as-
sociated with hypomethylation and active gene expression
Table 3 Chromatin regulators are enriched in genes that physically interact with MDGs
MDGs |Ti| N4 (# of physically interacting genes) N5 (# of physically
interacting genes in list A)
Enrichment PvalueA
i
TP53 8 923 192 0
PTEN 3 224 19 0.00035
RB1 2 250 64 0
NF1 2 29 3 0.079
CTNNB1 2 364 63 0
HRAS 2 86 6 0.08
BRAF 2 54 8 0.00053
IDH1 2 49 7 0.0015
NRAS 2 36 3 0.13
RNF43 2 18 7 1.4e-06
ZBTB20 2 17 1 0.45
CDH1 2 144 18 2.9e-06
|Ti|: number of tumor types whose genome-wide methylation levels are significantly associated with the mutation status of CDG i;
N4: number of genes physically interact with MDG i;
N5: number of genes physically interact with MDG i that are also in list A;
Enrichment PvalueA
i is calculated using a hypergeometric distribution testing if genes in list A are enriched among selected physically interacting genes.
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and heterochromatic state is associated with hypermethy-
lation and repressed gene expression [24].
We also investigated the consistency of the differential
gene expression and DNA methylation patterns across
tumor types. For each CDG, for every pair of tumor types
in which it is mutated in more than five samples, we
tested using a hypergeometric distribution if the number
of overlapping target genes that are differentially methyl-
ated by the mutation of the CDG is larger than expected.
We then reported the median p-values (Table 5) from all
pairs of two tumor types and repeated the same analysis
for differential expression. Both median p-values for dif-
ferential expression and methylation are ‘0’ or close to ‘0’
for most CDGs, which indicates that the differential ex-
pression or methylation associated with CDGs are consist-
ent across tumor types. Note that NSD1 gene was only
mutated in one tumor type.
Our findings on how CDG mutations contribute to
pan-cancer-associated epigenomic alterations and tran-
scriptomic alterations suggest that there are potentially
three mechanisms (Fig. 4): 1) genome-wide methylation
and expression changes are associated with changes in
Table 4 Identified 29 EDGs
EDGs ∣A′i∣ ∣Ei∣ p′i Bi E
−
i E
þ
i
TP53 14 11 < e-06 both HNSC LGG SARC BLCA BRCA COAD GBM KIRC LIHC LUAD STAD
PTEN 14 1 0.00299 up LGG
PIK3CA 11 2 0.00536 down BRCA STAD
RB1 10 3 9e-05 up BLCA LGG LUAD
ARID1A 10 2 0.00557 both STAD CESC
KRAS 8 4 4e-06 down COAD LUAD PAAD TGCT
KMT2D 8 1 0.0265 down STAD
NF1 6 1 0.00274 up LGG
CTNNB1 5 1 0.00572 down LIHC
†SETD2 5 0 0.00833 NA NA NA
BRAF 4 2 1.1e-05 down COAD THCA
EGFR 4 2 5.3e-05 up LGG LUAD
HRAS 4 3 7e-05 down HNSC PCPG THCA
CIC 3 1 < e-06 down LGG
IDH1 3 2 < e-06 both LGG GBM
RNF43 3 2 1e-06 down COAD STAD
ATRX 3 2 2e-06 both LGG GBM
CDH1 3 2 7e-06 both BRCA STAD
NRAS 3 2 0.000199 up TGCT THCA
KEAP1 3 1 0.000809 down LUAD
ZBTB20 3 2 0.00119 down COAD STAD
NOTCH1 3 2 0.00182 down HNSC LGG
SMARCA4 3 1 0.0108 up LUAD
GATA3a 3 1 0.0138 down BRCA
KMT2B 2 2 0.000317 down COAD STAD
KIT 2 1 0.000889 down TGCT
FUBP1a 1 1 < e-06 down LGG
SPOPa 1 1 < e-06 down PRAD
NSD1 1 1 0.000432 up HNSC
∣A′i∣ = number of tumor types in which EDG i is mutated in ≥ 5 samples with expression data;
∣Ei∣ = number of tumor types whose genome-wide expression levels are significantly associated with CDG i;
p0i ¼ p-value testing if CDG i is significantly associated with genome-wide expression changes across tumor types;
Bi is the direction of change of expression levels associated with the mutation status of CDG i;
Eþi ¼ tumor types that are up-regulated by CDG i, E−i = tumor types that are down-regulated by CDG i;
a : genes that are not overlapping driver genes.
†Note that SETD2 gene has a significant p-value p0i for testing association of genome-wide expression changes across multiple tumor types, but there is not a
specific tumor type in which SETD2 mutation is significantly associated with genome-wide expression changes.
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chromatin states induced by malfunctions of chroma-
tin regulators directly through mutations of these
genes; 2) or indirectly through mutations of other
genes that regulate the expression of chromatin regu-
lators; 3) or indirectly through mutations of other
genes with which chromatin regulators physically
interact with for epigenomic regulation.
Discussion
We conducted a pan-cancer analysis to identify CDGs
whose somatic mutations are associated with genome-wide
methylation/expression changes across multiple cancer
types. We used a straightforward method to compare
methylation/expression levels between mutated and
non-mutated groups of each CDG. The MDGs identified
highly overlap with the driver genes identified whose muta-
tion states are associated with genome-wide methylation
changes by Chen et al. [5] (these overlapping genes are
underlined in Table 1), where they used a different method,
the Principal Component Analysis (PCA). This provides
further validation of the MDGs results. However, our
method also identified several MDGs that were not identi-
fied by Chen et al. [5] including well-known chromatin reg-
ulators KMT2B, KMT2C, KMT2D and SMARCA4.
Table 5 Patterns of target genes’ promoter regions methylation and expression changes by mutations of the overlapping driver
genes across tumor types
Overlapping driver
genes
∣Ti∣ ∣Ei∣ ∣Ti ∩ Ei∣ ∣DM∣ ∣DE∣ jDM∩DEjjDEj (%) p(DM ∙ DE) p(−−) p(+−) p(−+) p(++) p.methyl p.exp
TP53 8 11 7 10389 10066 52 2.8e-32 1 9.7e-95 7.1e-65 1 0 0
PTEN 3 1 1 12259 10293 61 0.014 1 1e-15 1e-15 1 2.98e-10 0
RB1 2 3 1 9049 8062 46 0.0066 0.81 0.05 1e-15 1 0 0
PIK3CA 1 2 1 13933 5822 73 5e-12 1 1e-15 5.4e-05 1 1.93e-11 0
ARID1A 1 2 1 9487 8573 53 1e-15 0.98 1e-15 0.29 1 0 0
KRAS 1 4 1 15041 8427 73 1 1 7.5e-12 1 0.87 0 0
KMT2D 2 1 1 9802 8485 52 4.3e-14 1 1e-15 0.014 1 7.37e-10 0
NF1 2 1 1 10288 7435 53 9e-07 1 1e-15 1e-15 1 0 0
CTNNB1 2 1 1 7583 7591 37 0.64 1 1e-15 1 1 0 0
EGFR 1 2 1 13156 10606 66 0.0096 1 1e-15 1e-15 1 7.63e-07 0
HRAS 2 3 2 8758 6300 47 3.7e-19 0.97 7e-29 8.1e-20 1 0 0
BRAF 2 2 2 9120 10092 47 1.3e-06 0.96 1.3e-14 7e-29 1 0 9.99e-16
IDH1 2 2 2 10596 10134 55 6.6e-16 1 7e-29 7e-29 1 0 0
CIC 1 1 1 14066 12718 71 1.2e-08 1 1e-15 1e-15 1 0 0
NRAS 2 2 1 8413 10581 43 5.6e-06 1 1e-15 1e-15 1 0 0
RNF43 2 2 2 9978 9292 51 4.9e-08 1 3.9e-29 2e-14 1 0 0
ATRX 1 2 1 11646 12114 60 2.2e-16 1 1e-15 1e-15 1 0 0
ZBTB20 2 2 2 8415 6667 43 1.1e-10 0.94 8.6e-19 2.1e-09 1 0 0
NOTCH1 1 2 1 10225 7849 55 1e-15 1 1e-15 1e-15 1 0 0
CDH1 2 2 2 8634 8254 45 3.6e-16 1 1.1e-23 3.5e-26 1 0 0
KEAP1 1 1 1 10060 10030 50 0.4 1 1e-15 0.017 1 1.25e-12 0
SMARCA4 1 1 1 6118 6234 30 0.86 1 1e-15 0.93 1 1.11e-16 3.56e-11
KIT 1 1 1 15035 10164 74 0.87 1 4.4e-16 0.029 0.95 2.54e-09 1.07e-06
KMT2B 2 2 2 8066 6649 44 1.7e-24 1 7e-29 2.3e-24 1 0 0
NSD1 1 1 1 13052 8233 67 1.2e-10 0.55 1.9e-14 3.1e-10 1 NA NA
|DM|: number of differentially methylated genes averaged across Ti ∩ Ei tumor types;
|DE|: number of differentially expressed genes averaged across Ti ∩ Ei tumor types;
jDM∩DEj
jDEj (%): percent of differentially methylated target genes out of differentially expressed target genes, averaged across tumor types Ti ∩ Ei
p(DM ∙ DE): p-value testing if number of target genes that are differentially methylated and expression is larger than expected using a hypergeometric distribution
combined across tumor types Ti ∩ Eiusing the Fisher’s method.
p(−−), p(+−), p(−+), p(++): p-values that test if number of target genes with “--”,“+-”,“-+”,“++” pattern of methylation and expression changes is larger than
expected a using hypergeometric distribution combined across tumor types using the Fisher’s method.
p.methyl: median p-value from testing if the number of overlapping target genes that are differentially methylated by the mutation of the CDG between any pair
of two tumor types is larger than expected using a hypergeometric distribution.
p.exp: median p-value from testing if the number of overlapping target genes that are differentially expressed by the mutation of the CDG between any pair of
two tumor types is larger than expected using a hypergeometric distribution.
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The MDGs that we identified do not overlap the 18
master regulators identified by Yang et al. [8]. This is be-
cause they did not consider mutation data and focused
only on epigenetic enzymes, which exhibit consistently
differential expression and DNA methylation instability
correlation patterns across cancer types. However, as
Table 2 shows, the deregulation of the 18 master regula-
tors in list B are correlated with the mutation status of
the MDGs.
Interestingly, the MDGs and EDGs also include genes
that are associated with telomere length (TL) elongation
in cancers. Telomeres shorten with each cell division,
therefore, maintenance of telomere length is critical in
tumorigenesis. While telomere shortening is often
prevented by activation of telomerase reverse transcript-
ase (TERT), it is also prevented by a homologous
recombination-based process known as alternative
lengthening of telomeres (ALT), where remodeling of
the telomeric architecture may play a key role [25].
Floris et al. [26] recently performed a comprehensive
analysis of association between TL and somatic alter-
ations in cancers. To identify TERT-independent TL
regulation, they associated somatic alterations of 196
telomere-associated genes to TL ratio between match-
ing tumor and normal samples and found alterations
of ATRX, IDH1, TP53, BCOR, and RB1 were signifi-
cantly associated with relative TL elongation under
FDR<0.05. Our MDGs include four out of these five
genes, suggesting that chromatin remodeling plays an
important role in ALT.
In a recent review by Feinberg et al. [27], an epigenetic
functional classification system was introduced that clas-
sifies epigenetic genes into three categories 1) “epigen-
etic mediators”, which correspond to tumor progenitor
genes that are targets of epigenetic modification; 2) “epi-
genetic modifiers”, which modify DNA methylation or
chromatin structure; and 3) “epigenetic modulators”,
which influence activities of epigenetic modifiers to
destabilize epigenetic states.
Among the 32 MDGs, 8 are well-known chromatin
regulators that fall in the category of “epigenetic modi-
fiers”. The remaining 24 genes are considered as new
candidates of “epigenetic modulators” that are associated
with genome-wide methylation changes through regulat-
ing or interacting with chromatin regulators. Further
analysis that examined whether mutations of 12 MDGs
out of these 24 MDGs are associated with the expression
of known epigenetic modifiers across cancer types
supports our mechanistic hypothesis that some of these
MDGs are the ones that regulate expression of chroma-
tin regulators. Similarly, analysis that examined whether
chromatin regulators are enriched among genes that
physically interact with the 12 MDGs supports our
mechanistic hypothesis that some of these MDGs are
the ones that physically interact with chromatin
regulators.
Seven out of the 24 MDGs: PTEN, PIK3CA, KRAS,
HRAS, BRAF, NRAS, and KIT belong to the PI3K/AKT
signaling pathway which is known to target and change
the function of chromatin-modifying enzymes in SWI/
Fig. 4 Chromatin remodeling is one of the major mechanisms that amplify the impact of mutations in CDGs by global methylation and gene
expression changes
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SNF family members [28]. Previous studies provide
strong evidence that all these 7 genes are involved in
chromatin remodeling. BRAF mutation is known to be
tightly associated with a CpG island methylator pheno-
type (CIMP) and alteration of SWI/SNF chromatin re-
modeling pathway [29]. RAS genes which were classified
as epigenetic modifiers in the review by Feinberg et al.
induce global and local chromatin modifications [27].
There is also evidence for direct or indirect interactions
between chromatin regulators or chromatin themselves
and KIT [30], PIK3CA [31], and PTEN [32].
Another highly enriched function among the identified
MDGs is DNA repair. Eight of the 24 MDGs: TP53,
PTEN, RB1, FOXA1, BAP1, IDH1 and NF1 are known to
play a role in DNA repair, when DNA repair is known to
interact with chromatin remodeling. Studies of DNA re-
pair have uncovered that many histone modifications
occur after induction of a double-strand break [33].
TP53 binds to and regulates chromatin regulators, in-
cluding the methyltransferases KMT2A and KMT2D and
acetyltransferase KAT6A, resulting in genome-wide in-
creases of histone methylation and acetylation [34]. RB1
is also known to bind to and regulate DNA methyltrans-
ferase, histone methyltransferases and histone acetyl-
transferase [35]. FOXA1 is a pioneer transcription factor
whose recruitment to enhancers is associated with DNA
demethylation and induction of histone H3 lysine 4
methylation at these enhancers [36, 37]. It was recently
uncovered that FOXA1 interacts with components of
DNA repair complexes and that the FOXA1-associated
DNA repair complex is implicated in active DNA de-
methylation [38]. BAP1, which is critical for promoting
DNA repair by homologous recombination [39], plays a
key role in chromatin remodeling by mediating deubi-
quitination of histone H2A and HCFC1 [40]; IDH1 is
classified as an epigenetic modifier in the review by
Feinberg et al. [27] and its mutation is known to induce
the genome-wide alterations in DNA methylation by
inhibiting function of histone and DNA demethylases
[41], which also impairs DNA repair [42]. NF1 is also
known to participate in chromatin remodeling activities
[43].
For the rest of the MDGs, there is evidence supporting
many of their involvement in chromatin modification ei-
ther by interacting with histone modification enzymes or
chromatin remodeling complexes or with chromatin dir-
ectly, such as CDH1 [44], CTNNB1 [45], EGFR [46],
KEAP1 [47], NOTCH1 [48], STK11[49], and ZBTB20
[50]. Especially gene CIC, a transcription repressor in
the central nervous system identified as the MDG in
LGG, physically interacts with a histone methyltransfer-
ase KMT3A [51]. Note that CIC mutations are associ-
ated with hyper-methylation in LGG both among IDH1
wild-type tumors and IDH1 mutated tumors. Further
studies are needed to investigate if the observed clinical
and biological impact of CIC mutations in LGG is
through hyper-methylation of the epigenome.
In this study, we identified CDGs whose somatic
mutations are associated with pan-cancer genome-wide
methylation/expression changes by using a simple and
straightforward method to compare methylation or
expression levels between mutated and non-mutated
groups of each CDG. We acknowledge that the differ-
ence between the two groups may be confounded by
other factors, such as mutations in other genes as we
observed for TP53 and IDH1 in LGG tumors. However,
multivariate approaches such as regression models to
control for other gene mutations may not be feasible for
our purpose due to highly non-normal distribution of
methylation levels and sparseness of mutations. Al-
though we focused on associations of somatic mutations
with genome-wide methylation and expression changes
in this study, this approach can be readily modified to
examine association between copy number variations or
structural variations with genome-wide methylation and
expression changes.
Conclusions
Our pan-cancer analysis examining connections between
somatic mutation and DNA methylation/gene expres-
sion identified CDGs (32 MDGs and 29 EDGs) whose
somatic mutations are associated with genome-wide
methylation/expression changes across multiple cancer
types. Many of the identified MDGs are either chroma-
tin regulators or the ones that regulate the expression of
or physically interact with chromatin regulators.
Twenty-six out of the 29 EDGs overlap with the 32
MDGs. We further confirmed the enrichment of
target gene patterns being hyper-methylated and
down-regulated or hypo-methylated and up-regulated,
by the 26 overlapping genes. These findings highlight
that the dysregulation of chromatin regulation is an im-
portant mechanism that amplifies the impact of muta-
tions in CDGs by global methylation and gene
expression changes.
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Additional file 12: Figure S2. Significance of overlap between genome-
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changes by the overlapping driver genes, i.e., target genes that are hyper-
methylated and up-regulated by overlapping driver gene i, the “++” pattern;
target genes that are hyper- methylated and down-regulated by overlap-
ping driver gene i, the “+-” pattern; target genes that are hypo-methylated
and up-regulated by overlapping driver gene i, the “-+” pattern; and target
genes that are hypo-methylated and down- regulated by overlapping driver
gene i, the “–” pattern. (b) We calculated a p-value that tests if number of
target genes that are differentially methylated and expressed is larger than
expected using a hypergeometric distribution, and a p-value that tests if
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pression changes is larger than expected using a hypergeometric distribu-
tion, where we combined per tumor type p-values across tumor types
using the Fisher’s method. (TIF 94 kb)
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